Evaluation of Reference variability [Design Issues]

posted by Ohlbe – France, 2009-04-17 12:04 (5480 d 00:58 ago) – Posting: # 3553
Views: 2,946

Dear Nirali,

❝ Shall it be appropriate design to evaluate reference variability for EU regulatory? :confused:


This was not the approach recommended at the EGA meeting last October. The preferred approach was to have a 3- or 4-period replicate study, with the reference administered twice, and the test once or twice. It seems that they are afraid that you might run a messy trial to show a high variability with the reference alone, and use these results to justify wider acceptance limits in a clean 2x2 trial with test and reference afterwards.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,986 posts in 4,823 threads, 1,663 registered users;
56 visitors (0 registered, 56 guests [including 5 identified bots]).
Forum time: 13:02 CEST (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5